Infliximab and methotrexate in the treatment of rheumatoid arthritis

New England Journal of Medicine

Volumn 343, Issue 22, 2000, Pages 1594-1602

  Lipsky, Peter E ^a,l   Van Der Heijde, Desiree M F M ^b   St Clair, E William ^c   Furst, Daniel E ^d   Breedveld, Ferdinand C ^e   Kalden, Joachim R ^f   Smolen, Josef S ^g   Weisman, Michael ^h   Emery, Paul ⁱ   Feldmann, Marc ^j   Harriman, Gregory R ^k   Maini, Ravinder N ^j  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e LEIDEN UNIVERSITY   (Netherlands)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j CHARING CROSS HOSPITAL   (United Kingdom)

^k CENTOCOR INC   (United States)

^l NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYMPTOMATOLOGY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034735842     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011303432202     Document Type: Article

References (37)

1. Cytokines in autoimmunity
2. Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures
3. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis
4. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
5. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
6. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
7. Infliximab (chimeric antitumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
8. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein
9. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
10. Efficacy of low-dose methotrexate in rheumatoid arthritis
11. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
12. Rheumatoid arthritis
13. The American College of Rheumatology preliminary cote set of disease activity measures for rheumatoid arthritis clinical trials
14. Measurement of patient outcome in arthritis
15. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
16. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
17. Characterization and comparison of commercially available antinuclear antibody kits using single pattern index sera
18. An immunofluorescent method using Crithidia luciliae to detect antibodies to double-stranded DNA
19. Deoxyribonucleic acid antibody: A method to detect its primary interaction with deoxyribonucleic acid
20. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
21. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability
22. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis
23. Smallest detectable difference in radiological progression
24. Continuous progression of radiological destruction in seropositive rheumatoid arthritis
25. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
26. Radiographic progression in rheumatoid arthritis: A long-term prospective study of 109 patients
27. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
28. Cancer statistics, 1997
29. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
30. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease
31. The effectiveness of early treatment with "second-line" antirheumatic drugs: A randomized, controlled trial
32. Patterns of radiological progression in early rheumatoid arthritis: Results of an 8 year prospective study
33. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
34. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
35. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
36. Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage